Enliven Therapeutics, Inc. (ELVN)

Market Cap	1.07B
Revenue (ttm)	n/a
Net Income (ttm)	-85.21M
Shares Out	48.86M
EPS (ttm)	-1.90
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	109,729
Open	21.97
Previous Close	22.37
Day's Range	21.55 - 22.72
52-Week Range	10.90 - 30.03
Beta	n/a
Analysts	Strong Buy
Price Target	37.80 (+72.17%)
Earnings Date	Nov 13, 2024

About ELVN

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 12, 2020
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: ELVN
• Website: https://www.enliventherapeutics.com

Analyst Forecast

According to 5 analysts, the average rating for ELVN stock is "Strong Buy." The 12-month stock price forecast is $37.8, which is an increase of 72.17% from the latest price.

Price Target

$37.8

(72.17% upside)

Analyst Consensus: Strong Buy